COMP <GO>

IMRX vs EVMN // ALTMAN Z-SCORE & DEBT/EQUITY

Immuneering Corporation (Class A) (NASDAQ) VS. Evommune Inc. (NYSE) • 15-METRIC TALLY: IMRX 1 — EVMN 2

■ METRIC PARITY

LAST: $3.49 (-6.81%) • MKT CAP: $242.5M

balance-sheet

—

LAST: $6.01 (-10.70%) • MKT CAP: $244.2M

balance-sheet

5.87

15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IMRX VS. EVMN) EMERALD CELL = QUANTITATIVE EDGE

INSTITUTIONAL METRIC	IMRX	EVMN	SPREAD (A - B)	ADVANTAGE	DEDICATED URL
Gross Profit Margin	—	—	—	TIE	/gross-margins <GO>
Return on Invested Capital (ROIC)	-35.00%	-35.00%	0.00	TIE	/roic <GO>
EV/EBITDA & P/E Valuation	—	—	—	TIE	/valuation <GO>
Free Cash Flow Yield	-17.49%	—	—	TIE	/fcf-yield <GO>
Operating Margin	—	-60.00%	—	TIE	/operating-margins <GO>
Net Profit Margin	—	-60.00%	—	TIE	/net-margins <GO>
Revenue Growth (YoY)	—	85.70%	—	TIE	/revenue-growth <GO>
Dividend Yield & FCF Payout Safety	0.00%	0.00%	0.00	TIE	/dividend-safety <GO>
Altman Z-Score & Debt/Equity ACTIVE	—	5.87	—	TIE	/balance-sheet <GO>
Piotroski F-Score Quality	3/9	2/9	+1.00	IMRX	/piotroski-score <GO>
Options Implied Move & Put/Call Skew	—	—	—	TIE	/options-implied-move <GO>
RSI-14 & 200D SMA Momentum	44.8	49.4	-4.60	EVMN	/rsi-technicals <GO>
10Y Yield & FRED Macro Beta	—	—	—	TIE	/macro-sensitivity <GO>
Forward P/E Multiple	—	—	—	TIE	/forward-pe <GO>
Enterprise Scale & Market Cap	$242.5M	$244.2M	-$1.7M	EVMN	/market-cap <GO>

5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY

FISCAL YEAR	IMRX REV	EVMN REV	IMRX GROSS %	EVMN GROSS %	IMRX FCF	EVMN FCF
FY 2025	$166.3M	$13.0M	—	—	-$45.5M	-$76.7M
FY 2024	$179.4M	$7.0M	—	—	-$55.1M	-$58.3M
FY 2023	$163.6M	—	—	—	-$49.0M	—

FRED MACRO REGIME CORRELATION COMPARISON PEARSON r

IMRX // BETA —

EVMN // BETA —